使用EURO FORTA和STOPP/START标准优化COPD患者的药物治疗

E. A. Orlova
{"title":"使用EURO FORTA和STOPP/START标准优化COPD患者的药物治疗","authors":"E. A. Orlova","doi":"10.37489/2588-0519-2023-3-55-65","DOIUrl":null,"url":null,"abstract":"Relevance. Polypharmacy in taking medicines as one of the main consequences of comorbid pathology is a well-known risk factor for adverse drug reactions (ADRs). ADRs are often the cause of worsening disease course, disability, and mortality, especially in the elderly. This trend necessitates optimization of pharmacotherapy used in elderly patients using analytical algorithms for safety assessment. Objective. To analyze the safety of antibacterial and bronchodilator pharmacotherapy in COPD patients over 65 years old by means of comparative analysis of the data obtained according to EURO FORTA system methods and STOPP/START criteria. Methods. To conduct the study, a patient portrait was made on the basis of inpatient records data with the determination of Charlson and ADO indices. The influence of the severity of COPD course and comorbid pathology on polypharmacy was determined using the Spearman correlation coefficient (r). Evaluation of efficiency in the application of EURO FORTA and STOPP/START analytical criteria was carried out using a comparative analysis method. Statistical processing of the obtained data was performed using the StatPlus 7.0 program. Results. 113 inpatient records of elderly patients with moderately severe and severe COPD were studied. On the background of high severity of comorbid pathology, polypharmacy was observed in 102 patients (90.2%). The application of EURO FORTA and STOPP/START analytical tools in the analysis of bronchodilator and antibacterial therapy revealed 71 prescriptions of potentially unrecommended drugs in 61 (53,9%) patients. Conclusion. The analysis showed a high rate of prescribing drugs with significant risk in elderly patients. The conducted comparative analysis of two analytical tools for evaluation of the used pharmacotherapy EURO FORTA and STOPP/START demonstrated the necessity of their joint use to achieve the best results in ensuring safety of treatment of elderly patients, as they successfully complement each other.","PeriodicalId":34000,"journal":{"name":"Kachestvennaia klinicheskaia praktika","volume":"25 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimization of pharmacotherapy of COPD patients using EURO FORTA and STOPP/START criteria\",\"authors\":\"E. A. Orlova\",\"doi\":\"10.37489/2588-0519-2023-3-55-65\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Relevance. Polypharmacy in taking medicines as one of the main consequences of comorbid pathology is a well-known risk factor for adverse drug reactions (ADRs). ADRs are often the cause of worsening disease course, disability, and mortality, especially in the elderly. This trend necessitates optimization of pharmacotherapy used in elderly patients using analytical algorithms for safety assessment. Objective. To analyze the safety of antibacterial and bronchodilator pharmacotherapy in COPD patients over 65 years old by means of comparative analysis of the data obtained according to EURO FORTA system methods and STOPP/START criteria. Methods. To conduct the study, a patient portrait was made on the basis of inpatient records data with the determination of Charlson and ADO indices. The influence of the severity of COPD course and comorbid pathology on polypharmacy was determined using the Spearman correlation coefficient (r). Evaluation of efficiency in the application of EURO FORTA and STOPP/START analytical criteria was carried out using a comparative analysis method. Statistical processing of the obtained data was performed using the StatPlus 7.0 program. Results. 113 inpatient records of elderly patients with moderately severe and severe COPD were studied. On the background of high severity of comorbid pathology, polypharmacy was observed in 102 patients (90.2%). The application of EURO FORTA and STOPP/START analytical tools in the analysis of bronchodilator and antibacterial therapy revealed 71 prescriptions of potentially unrecommended drugs in 61 (53,9%) patients. Conclusion. The analysis showed a high rate of prescribing drugs with significant risk in elderly patients. The conducted comparative analysis of two analytical tools for evaluation of the used pharmacotherapy EURO FORTA and STOPP/START demonstrated the necessity of their joint use to achieve the best results in ensuring safety of treatment of elderly patients, as they successfully complement each other.\",\"PeriodicalId\":34000,\"journal\":{\"name\":\"Kachestvennaia klinicheskaia praktika\",\"volume\":\"25 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-10-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kachestvennaia klinicheskaia praktika\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37489/2588-0519-2023-3-55-65\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kachestvennaia klinicheskaia praktika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37489/2588-0519-2023-3-55-65","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

的相关性。多重用药是共病病理的主要后果之一,是众所周知的药物不良反应(adr)的危险因素。不良反应通常是恶化病程、残疾和死亡率的原因,尤其是在老年人中。这种趋势需要优化药物治疗用于老年患者使用分析算法进行安全性评估。目标。通过对EURO FORTA系统方法和STOPP/START标准数据的对比分析,分析65岁以上COPD患者抗菌药物和支气管扩张剂药物治疗的安全性。方法。为了进行研究,在住院记录数据的基础上,通过确定Charlson和ADO指数,对患者进行了画像。采用Spearman相关系数(r)确定COPD病程严重程度和共病病理对多药治疗的影响。采用对比分析方法评价EURO FORTA和STOPP/START分析标准的应用效率。使用StatPlus 7.0程序对所得数据进行统计处理。结果:对113例老年中、重度慢性阻塞性肺病住院病历进行分析。在合并症病理严重程度较高的背景下,102例(90.2%)患者出现多重用药。应用EURO FORTA和STOPP/START分析工具对61例患者的支气管扩张剂和抗菌药物进行分析,发现71张处方中存在潜在不推荐药物(53.9%)。结论。分析显示,老年患者的处方风险较高。通过对已使用药物治疗评估的两种分析工具EURO FORTA和STOPP/START的对比分析,证明了两者联合使用的必要性,因为它们能够很好地互补,以达到确保老年患者治疗安全的最佳效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Optimization of pharmacotherapy of COPD patients using EURO FORTA and STOPP/START criteria
Relevance. Polypharmacy in taking medicines as one of the main consequences of comorbid pathology is a well-known risk factor for adverse drug reactions (ADRs). ADRs are often the cause of worsening disease course, disability, and mortality, especially in the elderly. This trend necessitates optimization of pharmacotherapy used in elderly patients using analytical algorithms for safety assessment. Objective. To analyze the safety of antibacterial and bronchodilator pharmacotherapy in COPD patients over 65 years old by means of comparative analysis of the data obtained according to EURO FORTA system methods and STOPP/START criteria. Methods. To conduct the study, a patient portrait was made on the basis of inpatient records data with the determination of Charlson and ADO indices. The influence of the severity of COPD course and comorbid pathology on polypharmacy was determined using the Spearman correlation coefficient (r). Evaluation of efficiency in the application of EURO FORTA and STOPP/START analytical criteria was carried out using a comparative analysis method. Statistical processing of the obtained data was performed using the StatPlus 7.0 program. Results. 113 inpatient records of elderly patients with moderately severe and severe COPD were studied. On the background of high severity of comorbid pathology, polypharmacy was observed in 102 patients (90.2%). The application of EURO FORTA and STOPP/START analytical tools in the analysis of bronchodilator and antibacterial therapy revealed 71 prescriptions of potentially unrecommended drugs in 61 (53,9%) patients. Conclusion. The analysis showed a high rate of prescribing drugs with significant risk in elderly patients. The conducted comparative analysis of two analytical tools for evaluation of the used pharmacotherapy EURO FORTA and STOPP/START demonstrated the necessity of their joint use to achieve the best results in ensuring safety of treatment of elderly patients, as they successfully complement each other.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
22
审稿时长
2 weeks
期刊最新文献
Predicting the overall survival of patients with chronic lymphocytic leukemia in the dynamics of the disease Pharmacotherapy of glaucoma in terms of evidence-based medicine Optimization of pharmacotherapy of COPD patients using EURO FORTA and STOPP/START criteria Evidence-based medicine: new in the search for evidence Real-world assessment of treatment multiple myeloma patients on the example of one hematology center
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1